Applied Molecular Transport Inc.
AMTI evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AMTI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 4 of 6 signals
Financial data as of Sep 30, 2023.
Tracking 2 pipeline candidates for Applied Molecular Transport Inc..
Run Applied Molecular Transport Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Applied Molecular Transport Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 4 of 6 signals · derived from public data
12.5 months
D/E 0.23
Lead: Phase 2
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Governance
Frequently asked questions
What is Applied Molecular Transport Inc.'s lead drug candidate?
Applied Molecular Transport Inc.'s most advanced tracked candidate is amt-101 (Phase 2) for Chronic pouchitis, rheumatoid arthritis (RA).
Who is the CEO of Applied Molecular Transport Inc.?
Shawn Cross is the chief executive officer of Applied Molecular Transport Inc. (AMTI).
What therapeutic areas does Applied Molecular Transport Inc. focus on?
Applied Molecular Transport Inc. develops therapies across Immunology, Dermatology, Musculoskeletal.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.